Friday, 16 October 2026European Markets

NEW SOURCES ENERGY Stock Bullish By 33% In The Last 10 Sessions

Loading stream...

New Sources Energy (NSE), a Netherlands-based renewable energy company, has witnessed a remarkable development in their financial performance. Over 10 sessions, following three consecutive sessions of losses, the company's stock price saw an impressive 33.33% increase. This seems to coincide with a downturn in general market instability - the AEX-Index fell by 0.74% in the same period - possibly indicating potential opportunities for shareholders who are tolerant of risk.

Current Stock Position

In comparison to its 52-week high of EUR0.07, NSE's current stock remains notably lower, recently closing at EUR0.02. Additionally, the current value of NSE's stock does not align with the moving averages. The company's stock is notably less than both the 50-day and 200-day moving averages of EUR0.02 and EUR0.05, respectively.

Return on Equity Concerns

Return on Equity (ROE), a crucial indicator of both financial health and investor returns, has caused concern at NSE. The company reflected an ROE of -288.52% over its trailing twelve month period. This poor performance could potentially indicate issues arising from ineffective management or negative earnings, either of which could severely impact investor confidence.

Recent Volatility

Over recent periods, NSE's stock has experienced varying degrees of volatility. In the past week, month and quarter, intraday average variations showed intraday average differences of -7.78%, -1.14% and 11.41%, respectively. Interestingly, the highest level of volatility occurred in the last quarter, at 11.41%.

Investment Considerations

It's crucial for investors to fully understand NSE's performance and financial health in order to make informed investment decisions. Recent volatility in its stock price and the negative ROE signal potential risks, but simultaneously, these indicators may represent potential returns for investors who are willing to take on more risk.

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com